Drug Insights

Using Synapse for Your Guaifenesin Research: An Easy Guide

22 February 2024
2 min read

Guaifenesin, approved for medical use in Japan in 1949, is an expectorant medication found in numerous over-the-counter products. Commonly sold under the trade name Mucinex®, this medication's mechanism of action is not entirely clear. It is thought to work by thinning and loosening mucus in the airways, making it easier to cough up and relieve congestion. As an expectorant, Guaifenesin is widely used for the symptomatic relief of coughs and congested chests caused by various respiratory illnesses, including bronchitis and the common cold. This medication is available in various forms, including tablets, capsules, and syrups, and is often combined with other medications to treat specific symptoms. Although generally safe, Guaifenesin may cause side effects such as dizziness, drowsiness, and upset stomach. Click on the image below to begin the exploration journey of Guaifenesin through the Synapse database!

图形用户界面, 文本, 应用程序, 电子邮件

描述已自动生成

You can search for the latest pharmaceutical information such as drugs, targets, patents, transactions, clinical results, etc. through the Synapse database. Come and experience it!

图形用户界面, 文本, 应用程序, 聊天或短信

描述已自动生成

Artax Begins Phase 2a Psoriasis Trial with First Participant Dosed with AX-158
Latest Hotspot
3 min read
Artax Begins Phase 2a Psoriasis Trial with First Participant Dosed with AX-158
22 February 2024
Artax has initiated the dosing of the inaugural participant in their Phase 2a clinical study for Psoriasis, assessing the effects of compound AX-158.
Read →
Accessing Ketorolac Information on Synapse: A Step-by-Step Approach
Drug Insights
2 min read
Accessing Ketorolac Information on Synapse: A Step-by-Step Approach
22 February 2024
Ketorolac Tromethamine, or Toradol®, is an NSAID used to treat moderate to severe pain.
Read →
Otsuka Announces AVP-786 Trial Results for Alzheimer's Agitation
Latest Hotspot
3 min read
Otsuka Announces AVP-786 Trial Results for Alzheimer's Agitation
21 February 2024
Otsuka Reveals Key Outcomes from Final Stage Trial of AVP-786 for Managing Alzheimer’s-Related Dementia Agitation.
Read →
Maximize Your Synapse Use: Your Guide to Searching Olanzapine
Drug Insights
2 min read
Maximize Your Synapse Use: Your Guide to Searching Olanzapine
21 February 2024
Zyprexa® (Olanzapine), an antipsychotic, is commonly used to treat schizophrenia, bipolar 1, and related agitation.
Read →
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.